Resistance
ROS1-positive NSCLC
ORR
n=12
Intracranial
(target +
non-target
lesions) n=7
Intracran
ial
(target
lesions)
n=5
Objective Response
Rate, n (%)
6 (50) 4 (57)
4 (80)
Median PFS, months
7.0
Median Duration of
Response, months
12.0
Felip E, et al. WCLC 2016; Drilon et al. AACR 2016
LORLATINIB ENTRECTINIB
